X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the merger, the company will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.
Lead Product(s): ORKA-001
Therapeutic Area: Dermatology Product Name: ORKA-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: ARCA Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger April 03, 2024
Details:
The net proceeds will be used to advance Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.
Lead Product(s): ORKA-001
Therapeutic Area: Dermatology Product Name: ORKA-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fairmount
Deal Size: $275.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 03, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
